Abstract:Hepatitis B virus (HBV) infection is the leading cause of chronic hepatitis B (CHB), liver cirrhosis (LC), and hepatocellular carcinoma (HCC). This study reveals a distinct mechanism underlying the regulation of HBV replication. HBV activates homeobox A10 (HoxA10) in human hepatocytes, leukocytes, peripheral blood mononuclear cells (PBMCs), HepG2-NTCP cells, leukocytes isolated from CHB patients, and HBV-associated HCC tissues. HoxA10 in turn represses HBV replication in human hepatocytes, HepG2-NTCP cells, and BALB/c mice. Interestingly, we show that during early HBV infection, p38 mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription 3 (STAT3) were activated to facilitate HBV replication; however, during late HBV infection, HoxA10 was induced to attenuate HBV replication. Detailed studies reveal that HoxA10 binds to p38 MAPK, recruits SH2-containing protein tyrosine phosphatase 1 (SHP-1) to facilitate SHP-1 in catalyzing dephosphorylation of p38 MAPK/STAT3, and thereby attenuates p38 MAPK/STAT3 activation and HBV replication. Furthermore, HoxA10 binds to the HBV enhancer element I (EnhI)/X promoter, competes with STAT3 for binding of the promoter, and thereby represses HBV transcription. Taken together, these results show that HoxA10 attenuates HBV replication through repressing the p38 MAPK/STAT3 pathway by two approaches: HoxA10 interacts with p38 MAPK and recruits SHP-1 to repress HBV replication, and HoxA10 binds to the EnhI/X promoter and competes with STAT3 to attenuate HBV transcription. Thus, the function of HoxA10 is similar to the action of interferon (IFN) in terms of inhibition of HBV infection; however, the mechanism of HoxA10-mediated repression of HBV replication is different from the mechanism underlying IFN-induced inhibition of HBV infection. IMPORTANCE Two billion people have been infected with HBV worldwide; about 240 million infected patients developed chronic hepatitis B (CHB), and 650,000 die each year from liver cirrhosis (LC) or hepatocellular carcinoma (HCC). This work elucidates a mechanism underlying the control of HBV replication. HBV infection activates HoxA10, a regulator of cell differentiation and cancer progression, in human cells and patients with CHB and HCC. HoxA10 subsequently inhibits HBV replication in human tissue culture cells and mice. Additionally, HoxA10 interacts with p38 MAPK to repress the activation of p38 MAPK and STAT3 and recruits and facilitates SHP-1 to catalyze the dephosphorylation of p38 MAPK and STAT3. Moreover, HoxA10 competes with STAT3 for binding of the HBV X promoter to repress HBV transcription. Thus, this work reveals a negative regulatory mechanism underlying the control of HBV replication and provides new insights into the development of potential agents to control HBV infection.

HBV confers innate immune evasion through triggering HAT1/acetylation of H4K5/H4K12/miR‐181a‐5p or KPNA2/cGAS‐STING/IFN‐I signaling

O-GlcNAcylation of SAMHD1 Indicating a Link between Metabolic Reprogramming and Anti-HBV Immunity

HBV Inhibits LPS-induced NLRP3 Inflammasome Activation and IL-1β Production Via Suppressing the NF-κB Pathway and ROS Production.

Hepatitis B Virus Polymerase Disrupts K63-Linked Ubiquitination of STING to Block Innate Cytosolic DNA-Sensing Pathways

The Hepatitis B Virus X Protein Disrupts Innate Immunity by Downregulating Mitochondrial Antiviral Signaling Protein

Simultaneous or prior activation of intrahepatic type I interferon signaling leads to hepatitis B virus persistence in a mouse model

Hepatitis B Virus Evades Immune Recognition Via RNA Adenosine Deaminase ADAR1-mediated Viral RNA Editing in Hepatocytes

HAT1 signaling confers to assembly and epigenetic regulation of HBV cccDNA minichromosome

Hepatocyte nuclear factor 1α downregulates HBV gene expression and replication by activating the NF-κB signaling pathway

PD-L1 upregulation by IFN-α/γ-mediated Stat1 suppresses anti-HBV T cell response

Hepatitis B Virus e Antigen Activates the Suppressor of Cytokine Signaling 2 to Repress Interferon Action

Mitochondrial HIGD1A inhibits hepatitis B virus transcription and replication through the cellular PNKD‐NF‐κB‐NR2F1 nexus

Hepatitis B Virus Inhibits Intrinsic RIG-I and RIG-G Immune Signaling Via Inducing Mir146a

Mitochondrial HIGD1A Inhibits Hepatitis B Virus Transcription and Replication Through the Cellular PNKD-NF-B-NR2F1 Nexus

Hepatitis B Virus Hijacks CTHRC1 to Evade Host Immunity and Maintain Replication

HoxA10 Facilitates SHP-1-Catalyzed Dephosphorylation of P38 MAPK/STAT3 to Repress Hepatitis B Virus Replication by a Feedback Regulatory Mechanism

Hepatitis C Virus Ns4b Blocks the Interaction of Sting and Tbk1 to Evade Host Innate Immunity

Innate Immune Evasion by Hepatitis B Virus-Mediated Downregulation of TRIF

Epigenetic addition of m5C to HBV transcripts promotes viral replication and evasion of innate antiviral responses

Translatomic profiling reveals novel self-restricting virus-host interactions during HBV infection

The hijacking of HBV by small extracellular vesicles inhibits M1 macrophages to facilitate immune evasion